Haemonetics Corp Discloses Supply Agreement With CSL

What Happened
Haemonetics Corp (filed Aug. 18, 2026, Item 7.01 Regulation FD Disclosure) announced a supply agreement with CSL under which CSL may use Haemonetics’ NexSys PCS® devices with Persona® PLUS technology and purchase related disposables in the United States. The agreement is non‑exclusive and contains no minimum purchase commitments. Haemonetics expects CSL to transition a portion of its U.S. plasma collection centers to these devices, but the scope and timing are not yet determined.

Key Details

• Filing date: August 18, 2026 (Form 8‑K, Item 7.01, Regulation FD Disclosure).
• Product: NexSys PCS® devices with Persona® PLUS technology and related disposables.
• Commercial terms: Non‑exclusive supply agreement; no minimum purchase commitments.
• Guidance/Timing: Haemonetics is not updating fiscal 2027 guidance now and expects to provide an update on the agreement’s anticipated financial impact on its second fiscal quarter earnings call in November 2026.

Why It Matters
This agreement signals potential new commercial adoption of Haemonetics’ plasma collection devices by a large customer (CSL), which could increase product and disposable sales over time. Because the deal is non‑exclusive and includes no minimums, immediate revenue impact is uncertain; Haemonetics will provide more detail and any guidance updates on its Q2 fiscal 2027 earnings call in November 2026.